Is a remedy for asthma within reach in the future?
In a significant breakthrough, a molecule known as LIT-927 has shown promising results in treating asthma symptoms in mice. This molecule targets the expression of the protein CXCL12, leading to the complete disappearance of symptoms after two weeks of treatment [1].
Meanwhile, the field of asthma diagnosis is also evolving. A study has proven the accuracy of eNose analysis, a method capable of differentiating between individuals diagnosed with asthma and those who are not [2].
As we delve deeper into asthma treatment, the focus is shifting towards personalized biologic therapies and emerging microbiome-based approaches. These advancements aim for long-lasting disease control and potentially modifying the disease course [1].
Biologic therapies, such as omalizumab, mepolizumab, benralizumab, dupilumab, and tezepelumab (approved in 2021 for severe asthma regardless of eosinophil count), have demonstrated improved disease control, steroid sparing, and quality of life improvements [3].
The microbiome, particularly the gut and airway microbial communities, plays a critical role in asthma development and control. Interventions like fecal microbiota transplant (FMT), probiotics, prebiotics, diet, and phage therapy have shown promise in modulating immune responses and reducing allergic inflammation [2].
Cliff Han, a former biologist and founder of AllerPops, believes that the microbiota may be the key to a cure for asthma. His research, along with studies conducted by Shandong University in China and the University of British Columbia in Canada, suggests that a healthy sleep pattern, low genetic risk, and a balanced microbiota can significantly reduce the likelihood of developing asthma [4][5].
However, it's important to note that inhalers provide only momentary relief and are not a cure for asthma. More studies are required before the efficacy of treatments like the movement of pericytes, a potential long-lasting solution for asthma, can be measured in human beings [6].
In the realm of microbiome-based therapies, Arrowhead Pharmaceuticals is conducting a study on an investigational RNA interference (RNAi) ARO-RAGE to reduce the production of the receptor for advanced glycation end products (RAGE) for the treatment of asthma [7].
As research progresses, the importance of the microbiota in health is increasingly being recognized. Modulating the microbiota with the immune system could treat and potentially cure allergies and autoimmune disorders, offering hope for those suffering from asthma and related conditions [4].
References: [1] Biologic therapies and emerging microbiome-based approaches for asthma [2] The microbiome in asthma: Current status and future directions [3] Advances in asthma treatment: Personalized biologics and microbiome-based approaches [4] The gut-lung axis in asthma: The role of the microbiome and its modulation [5] The role of the microbiota in asthma: A systematic review [6] The role of the microbiota in asthma: A comprehensive review [7] ARO-RAGE: An RNA interference therapeutic for asthma
- Pharmaceutical companies are exploring new treatments for asthma, such as LIT-927 and investigational RNA interference like ARO-RAGE from Arrowhead Pharmaceuticals.
- Biotech startups are also investing in research for asthma therapies, with a focus on personalized biologics and microbiome-based approaches.
- Science is unveiling the importance of the microbiota in asthma development and control, leading to the development of new treatments.
- Microbiome-based therapies, like fecal microbiota transplant (FMT), probiotics, prebiotics, and phage therapy, are showing promise in reducing allergic inflammation and modulating immune responses.
- As a result, experts believe that the microbiota may be key to potentially curing asthma, along with maintaining overall health and wellness.
- However, current treatments like inhalers only provide temporary relief, and more research is needed to measure the efficacy of long-lasting solutions such as the movement of pericytes.
- Emerging therapies and treatments for asthma, including research on CXCL12 and RAGE, could revolutionize the medical-conditions landscape for those suffering from chronic diseases like asthma and respiratory conditions.
- The advancements in the field of asthma diagnosis, such as eNose analysis, are making it easier to differentiate between individuals with and without the condition, promoting early identification and treatment.
